ArticlePediatric research2026
Emerging role of non-coding RNAs as biomarkers and therapeutic targets in preterm infants with necrotizing enterocolitis.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Necrotizing enterocolitis (NEC) is a leading cause of morbidity and mortality in preterm infants, marked by intestinal necrosis, inflammation, hemorrhage, and impaired repair. Despite advances in neonatal care, early diagnostics and targeted therapies remain limited. Emerging evidence shows that non-coding RNAs (ncRNAs), including microRNAs, long ncRNAs, and tRNA-derived fragments, regulate key inflammatory, cell-death, angiogenic, and immune pathways in NEC. Distinct ncRNA signatures correlate with histopathology, and plasma-derived exosomal ncRNAs show promise as early biomarkers. Human milk exosomal microRNAs exhibit protective effects, while ncRNA-microbiome interactions may influence disease susceptibility. Larger studies using high-throughput sequencing are needed to advance biomarker-driven precision care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.